Ind-Swift Laboratories is a part of the Ind-swift Group and is based at Chandigarh, India. It has been promoted by Ind-Swift Limited in a joint venture with the Punjab State Industrial Development Corporation Limited (PSIDC). The group has established a strong reputation as innovators in the Indian pharmaceutical industry. 

Ind-Swift Laboratories Ltd. went public in 1997 and concentrated on the manufacturing of Active Pharmaceutical Ingredients (API). Its strength in organic synthetic chemistry resulted in the company emerging as the pioneer for a number of products both in the national and international markets. As the company built up vast skills in the area of research and development, quality systems as well as matters relating to regulatory compliance, it began establishing a presence in the highly regulated markets of the world.

Over a short period of time, Ind-Swift Laboratories Ltd. has emerged as a respectable and dependable supplier of Bulk-Actives in more than 40 countries. Not only are the company's plants built as per USFDA, the company employs current Good Manufacturing Practices (cGMP) also, which are recognised and accepted in the stringent regulated markets. This includes a responsible commitment to the environment.   To leverage its quality commitment, the Company has drawn out a long term strategy of emerging as a powerful force in the regulated markets as drugs worth over US$ 80 billion goes off patent during this decade.

The company's shares are listed on the Bombay, National, Ludhiana and Delhi stock exchanges.

Product range of the company include:

 * Macrolide antibiotics
 * Cardiovascular
 * Anti histamine
 * Anti diabetic
 * Analgesic
 * Aromatase inhibtors
 * Anti depressant
 * Alcohol absistence

Ind-Swift Laboratories Ltd.

Venus Remedies Ltd.

Kilitch Drugs (India) Ltd.

Albert David Ltd.

Nectar Lifesciences Ltd.

Lyka Labs Ltd.

Wanbury Ltd.

MEDICO

Medicamen Biotech Ltd.

Brooks Laboratories Ltd.

Sakar Healthcare Ltd.

Bafna Pharmaceuticals Ltd.

Windlas Biotech Ltd.

Alpa Laboratories Ltd.

Krebs Biochemicals & Industries Ltd.

Market Cap	541 Cr	ROE	10.6%
P/E Ratio(TTM)	10.3	EPS(TTM)	0.0
P/B Ratio	1.0	Dividend Yield	0.0%
Industry P/E	40.0	Book Value	92.4
		Face Value	10.0

Fundamentals